The approval of Casgevy, Vertex Pharmaceuticals Inc. and Crispr Therapeutics Inc.’s gene therapy for sickle cell disease, is a transformative moment in medicine. Not only is it the first Crispr-based drug to reach the market -- it’s a potentially life-altering advance for a patient population that has been for too long ignored and underserved by the medical establishment. Lyfgenia, a second gene therapy f...